Increased circulating phenylacetylglutamine levels elevates the predictive value of cardiovascular event risk in heart failure patients.

Plasma PAGln levels are an independent predictor of an increased risk of adverse cardiovascular events in HF. Our work could provide joint and complementary prognostic value to NT-proBNP levels in HF patients. This article is protected by copyright. All rights reserved.